---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039795"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:07:35.918637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q2 revenue $42M (+40% YoY); raises FY guidance to $191-197M

## Summary
- Revenue $42.0M, up 40% YoY; gross margin 81.7% vs 82.3% last year.
- Net loss per share ($0.20) improved from ($0.31) YoY; adjusted EBITDA loss ($7.7M).
- FY2023 revenue guidance raised to $191-197M, representing 35-39% growth.
- Direct sales channel grew to 79% of sales; reached 200 quota-carrying sales reps.
- Completed acquisition of RedPoint Medical3D assets for patient-specific instrumentation.

## SEC filing metadata
- accession: 0000950170-23-039795
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/tmci-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039795
- JSON: https://secwatch.observer/filing/0000950170-23-039795.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039795.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.
  - Period: quarter ended June 30, 2023
  - Net income: Second quarter net loss attributable to common stockholders was ($12.3) million
  - EPS: ($0.20) per share
  - Guidance: raised
  - Result: reported results
  source text: Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.
  - Period: quarter ended June 30, 2023
  - Net income: Second quarter net loss attributable to common stockholders was ($12.3) million
  - EPS: ($0.20) per share
  - Guidance: raised
  - Result: reported results
  source text: Second quarter net loss attributable to common stockholders was ($12.3) million, or ($0.20) per share, compared to ($17.2) million, or ($0.31) per share, for the same period of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported full-year 2023 results: revenue $191 million to $197 million. Guidance raised.
  - Period: full-year 2023
  - Revenue: $191 million to $197 million
  - Guidance: raised
  - Result: guidance update
  source text: Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company’s 2022 revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.